<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01417481</url>
  </required_header>
  <id_info>
    <org_study_id>Glycine in CF</org_study_id>
    <nct_id>NCT01417481</nct_id>
  </id_info>
  <brief_title>Effect of Glycine in Cystic Fibrosis</brief_title>
  <official_title>Evaluation of the Capability of a Glycine Oral Supplement for Diminishing Bronchial Inflammation in Children With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Enfermedades Respiratorias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Infantil de Mexico Federico Gomez</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Enfermedades Respiratorias</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate if glycine, orally administered in a daily dose of 0.5
      g/kg during 8 weeks, can ameliorate the airway inflammation in children with cystic fibrosis,
      as compared with placebo. During all of the study children will receive their usual treatment
      for cystic fibrosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background. Cystic fibrosis (CF) is a genetic disorder caused by a mutation in a gene that
      codifies for a chloride channel named &quot;cystic fibrosis transmembrane regulator&quot; (CFTR). In
      the lungs this results in thick and dehydrated mucus that tends to cause obstruction of the
      bronchial lumen. Neutrophils and proinflammatory substances have been detected in
      bronchoalveolar lavage fluid of children with CF who have no bacterial infection. This
      inflammation conditions a vicious circle in which airways are colonized by bacteria that
      further increase inflammation. Persistent inflammation leads to irreversible changes in
      airways, which become distorted. Therefore, a key step in CF treatment is reduction of airway
      inflammation, for which long-term use of corticosteroids, ibuprofen or macrolides may be
      indicated.

      Glycine and its antiinflammatory effect. Glycine is the most simple aminoacid, but it is also
      an agonist of the glycine receptors (GlyR) that, when activated, cause that cells such as
      Kupffer cells, alveolar macrophages and neutrophils decrease their sensitivity to
      proinflammatory agents. Orally administered glycine has been used for some illnesses, and it
      has been noticed that it is well tolerated. Considering that children with CF have an intense
      inflammatory process in the airways, here we propose to use glycine as antiinflammatory
      agent.

      Problem statement. Can a glycine oral supplement decrease the airway inflammation in children
      with CF?

      Hypothesis. Compared with placebo, a daily supplement of glycine administered for 8 weeks to
      children with CF produce a statistically significant decrease of bronchial inflammation,
      measured by the concentration of neutrophils and inflammatory substances in sputum and
      peripheral blood, as well as by respiratory symptoms and spirometry.

      Main objective: To determine whether a daily supplement of 0.5 g/kg glycine for 8 weeks
      significantly decrease the concentration, including neutrophils, interleukin(IL)-1β, IL-6,
      IL-8, tumor necrosis factor alpha (TNF-α), and myeloperoxidase, in sputum and peripheral
      blood of children with CF.

      Secondary Objectives:

        1. To determine if glycine can improve respiratory symptoms, including decreased amount and
           better fluidity of sputum.

        2. To determine if glycine can improve spirometric variables.

      Study design. This will be a randomized, placebo controlled, blinded, two-arms, cross-over
      clinical trial. Patients will receive glycine or placebo during the initial 8 weeks (initial
      phase), and after a 2 weeks washout period, they will receive the alternate treatment during
      another 8 weeks (second phase).

      Material and methods: Children with CF fulfilling the selection criteria will be studied if
      their parents accept their participation. They will be randomly assigned to one of two
      groups. The experimental group will receive glycine and the control group will receive
      placebo (sugar glass), both at doses of 0.5 g/kg divided in 3 doses per os dissolved in any
      liquid. At study entry and at weeks 4, 8, 10, 14 and 18 we will collect a 2 ml blood sample
      and a sputum sample, and the children will be submitted to spirometry. A daily symptom
      questionnaire will be filled by the parents.

      Statistical analysis: Each variable will be compared between experimental and control groups
      using Student's t test (or Mann Whitney U test if lacking normal distribution). Sample size:
      There are no previous studies that allow us to calculate a sample size. For convenience, it
      is estimated that 30 children can be included.

      Time to complete: 24 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Some of the researchers finished their participation in the study.
  </why_stopped>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Serum Concentration of Inflammatory Biomarkers (Other Than TNF-alpha)</measure>
    <time_frame>8 weeks</time_frame>
    <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Sputum Concentration of Inflammatory Biomarkers (Other Than IL-6 and G-CSF)</measure>
    <time_frame>8 weeks</time_frame>
    <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Serum Concentration of Inflammatory Biomarkers (TNF-alpha)</measure>
    <time_frame>8 weeks</time_frame>
    <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Sputum Concentration of Inflammatory Biomarkers (IL-6)</measure>
    <time_frame>8 weeks</time_frame>
    <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Sputum Concentration of Inflammatory Biomarkers (G-CSF)</measure>
    <time_frame>8 weeks</time_frame>
    <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Clinical Data Scores (Other Than Sputum Production, Dyspnea and Global Symptoms)</measure>
    <time_frame>8 weeks</time_frame>
    <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).
Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Score for Sputum Production, Dyspnea and Global Symptoms</measure>
    <time_frame>8 weeks</time_frame>
    <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).
In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Pulse Oximetry, FEV1/FVC, and FEF50.</measure>
    <time_frame>8 weeks</time_frame>
    <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in FEV1, FEF25, and FEFmax</measure>
    <time_frame>8 weeks</time_frame>
    <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Other Spirometric Variables</measure>
    <time_frame>8 weeks</time_frame>
    <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Glycine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a daily oral supplement of 0.5 g/kg glycine dissolved in water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a daily supplement of 0.5 g/kg sugar glass dissolved in water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glycine</intervention_name>
    <description>Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks</description>
    <arm_group_label>Glycine</arm_group_label>
    <other_name>aminoacetic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily oral administration of placebo (sugar glass) at a dose of 0.5 g/kg divided in three doses during 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>sugar glass</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children of either sex

          -  Between 5 and 15 years of age

          -  With CF diagnosed according to established criteria

          -  Without changes in the CF treatment in the last 30 days

          -  Without CF exacerbation in the last 30 days

          -  Without acute respiratory infection (e.g., common cold) in the last 15 days

          -  Informed consent letter signed by their parents or legal guardians

        Exclusion Criteria:

          -  Children with CF that had participated in a research protocol in the last 3 months

          -  Presence of serious adverse effects attributable to glycine, in which case the result
             will be considered as therapeutic failure in the statistical analysis

          -  Development of a CF exacerbation, in which case the available data so far collected
             will be included in the statistical analysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario H Vargas, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Enfermedades Respiratorias</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Infantil de México</name>
      <address>
        <city>Mexico DF</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigación Médica en Enfermedades Respiratorias, Hospital de Pediatría, CMN SXXI, IMSS</name>
      <address>
        <city>Mexico DF</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Respiratorias</name>
      <address>
        <city>Mexico DF</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Cohen-Cymberknoh M, Shoseyov D, Kerem E. Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med. 2011 Jun 1;183(11):1463-71. doi: 10.1164/rccm.201009-1478CI. Epub 2011 Feb 17. Review.</citation>
    <PMID>21330455</PMID>
  </reference>
  <reference>
    <citation>Wheeler MD, Ikejema K, Enomoto N, Stacklewitz RF, Seabra V, Zhong Z, Yin M, Schemmer P, Rose ML, Rusyn I, Bradford B, Thurman RG. Glycine: a new anti-inflammatory immunonutrient. Cell Mol Life Sci. 1999 Nov 30;56(9-10):843-56. Review.</citation>
    <PMID>11212343</PMID>
  </reference>
  <reference>
    <citation>Wheeler MD, Rose ML, Yamashima S, Enomoto N, Seabra V, Madren J, Thurman RG. Dietary glycine blunts lung inflammatory cell influx following acute endotoxin. Am J Physiol Lung Cell Mol Physiol. 2000 Aug;279(2):L390-8.</citation>
    <PMID>10926563</PMID>
  </reference>
  <reference>
    <citation>Garcia-Macedo R, Sanchez-Muñoz F, Almanza-Perez JC, Duran-Reyes G, Alarcon-Aguilar F, Cruz M. Glycine increases mRNA adiponectin and diminishes pro-inflammatory adipokines expression in 3T3-L1 cells. Eur J Pharmacol. 2008 Jun 10;587(1-3):317-21. doi: 10.1016/j.ejphar.2008.03.051. Epub 2008 Apr 8.</citation>
    <PMID>18499099</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 15, 2011</study_first_submitted>
  <study_first_submitted_qc>August 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2011</study_first_posted>
  <results_first_submitted>September 9, 2014</results_first_submitted>
  <results_first_submitted_qc>October 21, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 23, 2014</results_first_posted>
  <last_update_submitted>October 30, 2014</last_update_submitted>
  <last_update_submitted_qc>October 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Enfermedades Respiratorias</investigator_affiliation>
    <investigator_full_name>Mario H. Vargas</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <keyword>glycine</keyword>
  <keyword>airway inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients attending the Hospital Infantil de México and the Instituto Mexicano del Seguro Social (both in Mexico city) were recruited from March 7, 2012 to October 31, 2012. The two arms of the study were: 1) Glycine, then placebo, and 2) Placebo, then glycine.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Glycine, Then Placebo</title>
          <description>First intervention (8 weeks) with Glycine (0.5 g/kg/day divided in three doses).
Washout period of 2 weeks. Second intervention (8 weeks) with Placebo (sugar glass, 0.5 g/kg/day divided in three doses).</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Glycine</title>
          <description>First intervention (8 weeks) with Placebo (sugar glass, 0.5 g/kg/day divided in three doses).
Washout period of 2 weeks. Second intervention (8 weeks) with Glycine (0.5 g/kg/day divided in three doses).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Period (8 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The total number of patiens was fewer than planned mainly because other protocols were running concurrently. The protocolo had to be concluded because some of the researchers finished their participation.</population>
      <group_list>
        <group group_id="B1">
          <title>Glycine, Then Placebo</title>
          <description>First intervention (8 weeks) with Glycine (0.5 g/kg/day divided in three doses).
Washout period of 2 weeks. Second intervention (8 weeks) with Placebo (sugar glass, 0.5 g/kg/day divided in three doses).</description>
        </group>
        <group group_id="B2">
          <title>Placebo, Then Glycine</title>
          <description>First intervention (8 weeks) with Placebo (sugar glass, 0.5 g/kg/day divided in three doses).
Washout period of 2 weeks. Second intervention (8 weeks) with Glycine (0.5 g/kg/day divided in three doses).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>During the course of the study, inclusion criteria was expanded to include subjects older than 15 years of age.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.39" spread="5.82"/>
                    <measurement group_id="B2" value="11.00" spread="4.01"/>
                    <measurement group_id="B3" value="12.81" spread="5.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Clinical Data Scores (Other Than Sputum Production, Dyspnea and Global Symptoms)</title>
        <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).
Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg glycine dissolved in water during 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg placebo (sugar glass) dissolved in water during 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Clinical Data Scores (Other Than Sputum Production, Dyspnea and Global Symptoms)</title>
          <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).
Each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms.</description>
          <units>Percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cough questionnaire score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1" spread="12.6"/>
                    <measurement group_id="O2" value="89.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite questionnaire score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.1" spread="11.0"/>
                    <measurement group_id="O2" value="132.1" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Energy questionnaire score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.6" spread="7.4"/>
                    <measurement group_id="O2" value="111.5" spread="16.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Body weight</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.6" spread="1.1"/>
                    <measurement group_id="O2" value="103.6" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Height</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.5" spread="0.2"/>
                    <measurement group_id="O2" value="100.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.5" spread="6.0"/>
                    <measurement group_id="O2" value="98.1" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8" spread="5.5"/>
                    <measurement group_id="O2" value="109.0" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" spread="0.3"/>
                    <measurement group_id="O2" value="100.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Due to the cross-over, a paired analysis was done. The hypothesis was that glycine will improve variables, and thus significance was set at one-tail.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Serum Concentration of Inflammatory Biomarkers (Other Than TNF-alpha)</title>
        <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution.</description>
        <time_frame>8 weeks</time_frame>
        <population>From the 13 patients who initiated the study, some parents did not give consent for blood sampling, and some children refused the venous puncture at some visits. Thus, only a non-paired population of 9 children per group could be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg glycine dissolved in water during 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg placebo (sugar glass) dissolved in water during 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Concentration of Inflammatory Biomarkers (Other Than TNF-alpha)</title>
          <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution.</description>
          <population>From the 13 patients who initiated the study, some parents did not give consent for blood sampling, and some children refused the venous puncture at some visits. Thus, only a non-paired population of 9 children per group could be analyzed.</population>
          <units>log (percent change)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Myeloperoxidase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4361" spread="0.2184"/>
                    <measurement group_id="O2" value="-0.2906" spread="0.2877"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1635" spread="0.1467"/>
                    <measurement group_id="O2" value="-0.0352" spread="0.1294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2964" spread="0.1420"/>
                    <measurement group_id="O2" value="0.1470" spread="0.2223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0085" spread="0.2064"/>
                    <measurement group_id="O2" value="0.2255" spread="0.1865"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0356" spread="0.0613"/>
                    <measurement group_id="O2" value="0.0819" spread="0.0986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1466" spread="0.2981"/>
                    <measurement group_id="O2" value="-0.2364" spread="0.1761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3203" spread="0.1449"/>
                    <measurement group_id="O2" value="0.2603" spread="0.2117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0561" spread="0.1684"/>
                    <measurement group_id="O2" value="0.1953" spread="0.1849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>G-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0776" spread="0.1554"/>
                    <measurement group_id="O2" value="0.2272" spread="0.1983"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-gamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3272" spread="0.1761"/>
                    <measurement group_id="O2" value="0.3639" spread="0.2505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0836" spread="0.1041"/>
                    <measurement group_id="O2" value="0.0472" spread="0.0894"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0330" spread="0.1426"/>
                    <measurement group_id="O2" value="-0.0608" spread="0.0963"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>The hypothesis was that glycine will improve inflammatory biomarkers, and thus statistical significance was set at one-tail.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Sputum Concentration of Inflammatory Biomarkers (Other Than IL-6 and G-CSF)</title>
        <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution.</description>
        <time_frame>8 weeks</time_frame>
        <population>From the 13 patients who initiated the study, some children at some visits could not give an appropriate sputum sample. Thus, only a non-paired population of 9 (glycine group) and 11 (placebo group) children could be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg glycine dissolved in water during 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg placebo (sugar glass) dissolved in water during 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Sputum Concentration of Inflammatory Biomarkers (Other Than IL-6 and G-CSF)</title>
          <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution.</description>
          <population>From the 13 patients who initiated the study, some children at some visits could not give an appropriate sputum sample. Thus, only a non-paired population of 9 (glycine group) and 11 (placebo group) children could be analyzed.</population>
          <units>log (percent change)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Myeloperoxidase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1294" spread="0.2204"/>
                    <measurement group_id="O2" value="0.0669" spread="0.1725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0918" spread="0.1552"/>
                    <measurement group_id="O2" value="-0.0102" spread="0.1329"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0233" spread="0.0828"/>
                    <measurement group_id="O2" value="-0.0274" spread="0.1243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0161" spread="0.0482"/>
                    <measurement group_id="O2" value="0.0522" spread="0.0671"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2498" spread="0.1855"/>
                    <measurement group_id="O2" value="0.1304" spread="0.1864"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0611" spread="0.0852"/>
                    <measurement group_id="O2" value="0.1387" spread="0.1028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0824" spread="0.2311"/>
                    <measurement group_id="O2" value="0.0542" spread="0.0934"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0549" spread="0.0847"/>
                    <measurement group_id="O2" value="0.0074" spread="0.0849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1675" spread="0.1443"/>
                    <measurement group_id="O2" value="0.0677" spread="0.1250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1630" spread="0.1379"/>
                    <measurement group_id="O2" value="0.0953" spread="0.1049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0680" spread="0.0411"/>
                    <measurement group_id="O2" value="0.1140" spread="0.0823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IFN-gamma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0248" spread="0.0652"/>
                    <measurement group_id="O2" value="0.0649" spread="0.0730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCP-1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0042" spread="0.0694"/>
                    <measurement group_id="O2" value="0.2608" spread="0.2025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MIP-1beta</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0303" spread="0.1234"/>
                    <measurement group_id="O2" value="0.0977" spread="0.1207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNF-alpha</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0412" spread="0.1091"/>
                    <measurement group_id="O2" value="0.1568" spread="0.1393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0538" spread="0.0338"/>
                    <measurement group_id="O2" value="-0.0822" spread="0.0468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>The hypothesis was that glycine will improve inflammatory biomarkers, and thus statistical significance was set at one-tail.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Serum Concentration of Inflammatory Biomarkers (TNF-alpha)</title>
        <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution.</description>
        <time_frame>8 weeks</time_frame>
        <population>From the 13 patients who initiated the study, some parents did not give consent for blood sampling, and some children refused the venous puncture at some visits. Thus, only a non-paired population of 9 children per group could be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg glycine dissolved in water during 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg placebo (sugar glass) dissolved in water during 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Concentration of Inflammatory Biomarkers (TNF-alpha)</title>
          <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentages were log-transformed to adjust to a normal distribution.</description>
          <population>From the 13 patients who initiated the study, some parents did not give consent for blood sampling, and some children refused the venous puncture at some visits. Thus, only a non-paired population of 9 children per group could be analyzed.</population>
          <units>log (percent change)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3908" spread="0.2744"/>
                    <measurement group_id="O2" value="0.2035" spread="0.2384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.061</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>The hypothesis was that glycine will improve inflammatory biomarkers, and thus statistical significance was set at one-tail.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Sputum Concentration of Inflammatory Biomarkers (IL-6)</title>
        <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution.</description>
        <time_frame>8 weeks</time_frame>
        <population>From the 13 patients who initiated the study, some children did not expectorate at some visits. Thus, only a non-paired population of 9 children under glycine and 11 under placebo could be analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg glycine dissolved in water during 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg placebo (sugar glass) dissolved in water during 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Sputum Concentration of Inflammatory Biomarkers (IL-6)</title>
          <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution.</description>
          <population>From the 13 patients who initiated the study, some children did not expectorate at some visits. Thus, only a non-paired population of 9 children under glycine and 11 under placebo could be analyzed.</population>
          <units>log (percent change)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00007" spread="0.0677"/>
                    <measurement group_id="O2" value="0.1739" spread="0.0838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.068</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>The hypothesis was that glycine will improve inflammatory biomarkers, and thus statistical significance was set at one-tail.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Sputum Concentration of Inflammatory Biomarkers (G-CSF)</title>
        <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg glycine dissolved in water during 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg placebo (sugar glass) dissolved in water during 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Sputum Concentration of Inflammatory Biomarkers (G-CSF)</title>
          <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]). Then, percentage change was log-transformed to adjust to a normal distribution.</description>
          <units>log (percent change)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0819" spread="0.0790"/>
                    <measurement group_id="O2" value="0.1668" spread="0.1022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.040</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>The hypothesis was that glycine will improve inflammatory biomarkers, and thus statistical significance was set at one-tail.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Score for Sputum Production, Dyspnea and Global Symptoms</title>
        <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).
In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg glycine dissolved in water during 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg placebo (sugar glass) dissolved in water during 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Score for Sputum Production, Dyspnea and Global Symptoms</title>
          <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).
In the symptoms questionnaire, each respiratory symptom (Cough severity, Sputum features, Appetite, Dyspnea, and Energy perception) was evaluated in a 5-options Likert scale, ranging from 1 (better) to 5 (worse). The total score was computed by the simple sum of the five symptoms.</description>
          <units>Percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sputum questionnaire score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.0" spread="7.0"/>
                    <measurement group_id="O2" value="102.6" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea questionnaire score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.6" spread="7.5"/>
                    <measurement group_id="O2" value="103.8" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total questionnaire score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.7" spread="5.2"/>
                    <measurement group_id="O2" value="98.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Due to the cross-over, a paired analysis was done. The hypothesis was that glycine will improve variables, and thus significance was set at one-tail.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Pulse Oximetry, FEV1/FVC, and FEF50.</title>
        <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg glycine dissolved in water during 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg placebo (sugar glass) dissolved in water during 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Pulse Oximetry, FEV1/FVC, and FEF50.</title>
          <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).</description>
          <units>Percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Peripheral oxygen saturation (SpO2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.2" spread="2.5"/>
                    <measurement group_id="O2" value="98.9" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FEV1/FVC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.2" spread="2.9"/>
                    <measurement group_id="O2" value="94.9" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forced expiratory flow at 50%FVC (FEF50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.5" spread="10.4"/>
                    <measurement group_id="O2" value="93.1" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Due to the cross-over, paired analysis was done. The hypothesis was that glycine will improve variables, thus significance was set at one-tail.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in FEV1, FEF25, and FEFmax</title>
        <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg glycine dissolved in water during 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg placebo (sugar glass) dissolved in water during 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in FEV1, FEF25, and FEFmax</title>
          <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).</description>
          <units>Percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Forced expiratory volume at first second (FEV1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.7" spread="6.4"/>
                    <measurement group_id="O2" value="91.4" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forced expiratory flow at 25%FVC (FEF25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.9" spread="13.6"/>
                    <measurement group_id="O2" value="83.3" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maximal forced expiratory flow (FEFmax, PEFR)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.3" spread="6.1"/>
                    <measurement group_id="O2" value="91.2" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Due to the cross-over, a paired analysis was done. The hypothesis was that glycine will improve variables, and thus significance was set at one-tail.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Other Spirometric Variables</title>
        <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Glycine</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg glycine dissolved in water during 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All study participants receiving a daily oral supplement of 0.5 g/kg placebo (sugar glass) dissolved in water during 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Other Spirometric Variables</title>
          <description>To correct for the baseline variability, all measurements were expressed as percentage of baseline (value at week 8 with respect to baseline value [beginning of the glycine or placebo period, respectively]).</description>
          <units>Percentage of baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Forced vital capacity (FVC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.1" spread="4.1"/>
                    <measurement group_id="O2" value="100.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forced expiratory flow at 75%FVC (FEF75)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111.8" spread="11.7"/>
                    <measurement group_id="O2" value="108.9" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>t-test, 1 sided</method>
            <method_desc>Due to the cross-over, a paired analysis was done. The hypothesis was that glycine will improve variables, and thus significance was set at one-tail.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Weeks 4 and 8 of each study arm.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Glycine</title>
          <description>Patients received a daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks, dissolved in any liquid.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients received a daily oral supplement of sugar glass at a dose of 0.5 g/kg divided in three doses during 8 weeks, dissolved in any liquid.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mario H. Vargas</name_or_title>
      <organization>Instituto Nacional de Enfermedades Respiratorias</organization>
      <phone>(+55)54871771</phone>
      <email>mhvargasb@yahoo.com.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

